Long-term effect of active parenteral nutrition support regimen in preterm infants with a gestational age of <34

Ren-Hui Jiang1, Yu-Jie Shen, Xiao-Chen Liu

  • 1Department of Child Health Care, Children's Hospital of Chongqing Medical University, Chongqing 400014, China.

Insights

Early, high-dose parenteral nutrition in preterm infants (<34 weeks gestation) significantly improved long-term neurodevelopmental outcomes. This active nutritional support regimen enhanced motor and social behaviors by 13 months of age.

Area of Science:

  • Neonatal Medicine
  • Pediatric Nutrition
  • Neurodevelopmental Pediatrics

Background:

  • Preterm infants, particularly those with a gestational age less than 34 weeks, face significant risks for suboptimal neurodevelopment.
  • Early nutritional support is critical for the growth and development of these vulnerable infants.
  • Parenteral nutrition (PN) is often essential, but optimal strategies for macronutrient delivery require further investigation.

Purpose of the Study:

  • To evaluate the long-term neurodevelopmental effects of an active parenteral nutrition support regimen in preterm infants (<34 weeks gestation).
  • To compare the developmental outcomes between infants receiving active PN versus conventional PN.

Main Methods:

  • A cohort of preterm infants (<34 weeks gestation), admitted within 24 hours of birth, was divided into active PN and conventional PN groups based on early fat emulsion and amino acid doses.
  • Infants were assessed at 6 and 13 months corrected age using the Gesell Development Scale.
  • Physical development indices (weight, height, head circumference) were also monitored.

Main Results:

  • At 6 months, the active PN group showed significantly higher developmental quotients in gross motor, fine motor, and personal-social domains compared to the conventional PN group.
  • At 13 months, the active PN group continued to demonstrate superior developmental quotients in adaptive behavior, gross motor, and personal-social domains.
  • No significant differences in physical growth parameters (weight, height, head circumference) were observed between the groups throughout the follow-up period.

Conclusions:

  • An active parenteral nutrition strategy, characterized by high doses of fat emulsion and amino acids initiated within 24 hours of birth, positively impacts long-term neurodevelopment in preterm infants (<34 weeks gestation).
  • This approach appears to enhance key neurodevelopmental trajectories without adversely affecting physical growth.
Abstract

Related Concept Videos

Parentral Nutrition: Centeral and Peripheral Parental Nutrition01:27

Parentral Nutrition: Centeral and Peripheral Parental Nutrition

Parenteral Nutrition (PN) delivers essential nutrients directly into the bloodstream, bypassing the digestive system. It is commonly used for individuals with severe digestive disorders or conditions that prevent normal nutrient absorption.
PN can be administered through two primary routes:
1. Central Parenteral Nutrition (CPN):
CPN involves delivering a high concentration of nutrients through a large vein. This is typically achieved using a Peripherally Inserted Central Catheter (PICC) or,...
346
Enteral Nutrition II: Nasointestinal and Gastrostomy Feeding01:15

Enteral Nutrition II: Nasointestinal and Gastrostomy Feeding

Enteral nutrition encompasses various methods of delivering nutrition directly to the gastrointestinal (GI) tract, bypassing traditional oral intake. It is particularly beneficial for patients who cannot eat by mouth but have a functioning digestive system. Key methods include nasointestinal feeding, gastrostomy, and jejunostomy, each suited to different clinical scenarios based on the patient's needs and condition.
Nasointestinal Feeding
Nasointestinal feeding involves placing a tube...
341
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
15
Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
3.0K
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
15
Parenteral Anesthetics: Overview01:24

Parenteral Anesthetics: Overview

Intravenous anesthetics are drugs administered parenterally to induce anesthesia or sedation. Propofol is a widely used agent formulated as a 1% emulsion in soybean oil, glycerol, and egg phosphatide. It induces rapid anesthesia primarily due to its rapid distribution from the bloodstream to target tissues and is metabolized in the liver. However, it can cause significant pain on injection and hypertriglyceridemia. Fospropofol, a water-based prodrug of propofol, lacks these adverse effects.
323